DP Diagnostic Products

Diagnostic Products Corporation (NYSE:DP) announced today that it has scheduled a conference call to discuss the Company's financial results of its first quarter 2006 on Thursday, April 27, 2006, at 11:30 a.m. Eastern daylight time (8:30 a.m. PDT). The Company plans to release its financial results before the market opens on Thursday. If you are interested in participating in the call, please call 719-457-2731 or 800-481-9591 on the day of the conference, at least ten minutes prior to the conference in order for the operator to tie you into the call. The operator will ask you to identify the call with the company name Diagnostic Products Corporation-Jim Brill. An "instant replay" of the call will be available until May 5. If you would like to take advantage of this special service, you can access it via 719-457-0820 or 888-203-1112 and the code: "5707457." It usually takes two hours following the conference to set up the recording. About Diagnostic Products Corporation Diagnostic Products Corporation, founded in 1971, is a leader in the global in vitro diagnostics market. DPC's product offering includes the widely accepted IMMULITE(R) series of immunoassay systems, more than 75 immunoassays and an expanding menu of essential specific allergens and allergy panels that are run just like other immunoassays. DPC also designs and manufactures automated laboratory instrumentation and automation solutions that provide fast, accurate results while enabling our customers to do "more with less" in a leaner laboratory. DPC's combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries. Additional Company information can be found on DPC's website at www.dpcweb.com. Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include governmental or other action relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets, including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.